Autopsy report · NCT03635996
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
Cause of deathFunding or business
“Study was stopped by the Sponsor”
Life of this trial
- Registered 4 months before it started.
- Ran for about 1 year 11 months before it stopped.
- 169 participants enrolled.
- Results were posted on the registry 2 years 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Milestone Pharmaceuticals Inc.
- Sponsor type
- University, hospital or other
- Conditions
- Paroxysmal Supraventricular Tachycardia
- Interventions
- Etripamil NS 70 mg; Aptar Pharma Nasal Spray Bidose System
- Participants
- 169
- Sites
- 34
- Countries
- Canada, United States
Trials that died the same way
- A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease
“Sponsor stopped the study” - the Health Crisis at the Healthcare Professionals, Careers and Non-careers, a Month After the Containment Period
“the sponsor decided to stop the study” - Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum
“The sponsor stopped the study.” - Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
“Study has been stopped by sponsor decision.” - Multi-center Complex Atrial Tachycardia High-Resolution Mapping Registry (MATH)
“The sponsor has decided to stop the study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.